EUVIMEDEUVIMED entdecken
Open Access

Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells

Brian T Orcutt-Jahns iD, Peter C Emmel iD, Eli M Snyder, Scott D Taylor iD, Aaron S Meyer iD

Science Signaling · 2023

DOI: 10.1126/scisignal.adg0699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Signaling, 2023. Verfasst von Brian T Orcutt-Jahns und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Interleukin-2, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cytokine interleukin-2 (IL-2) has the potential to treat autoimmune disease but is limited by its modest specificity toward immunosuppressive regulatory T (T reg ) cells. IL-2 receptors consist of combinations of α, β, and γ chains of variable affinity and cell specificity. Engineering IL-2 to treat autoimmunity has primarily focused on retaining binding to the relatively T reg -selective, high-affinity receptor while reducing binding to the less selective, low-affinity receptor. However, we found that refining the designs to focus on targeting the high-affinity receptor through avidity effects is key to optimizing T reg selectivity. We profiled the dynamics and dose dependency of signaling responses in primary human immune cells induced by engineered fusions composed of either wild-type IL-2 or mutant forms with altered affinity, valency, and fusion to the antibody Fc region for stability. T reg selectivity and signaling response variations were explained by a model of multivalent binding and dimer-enhanced avidity—a combined measure of the strength, number, and conformation of interaction sites—from which we designed tetravalent IL-2–Fc fusions that had greater T reg selectivity in culture than do current designs. Biasing avidity toward IL2Rα with an asymmetrical multivalent design consisting of one α/β chain–binding and one α chain–binding mutant further enhanced T reg selectivity. Comparative analysis revealed that IL2Rα was the optimal cell surface target for T reg selectivity, indicating that avidity for IL2Rα may be the optimal route to producing IL-2 variants that selectively target T regs .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2T-Lymphocytes, RegulatoryHumansReceptors, Interleukin-2Interleukin-2 Receptor alpha SubunitCytokines

Substanzen

Interleukin-2Receptors, Interleukin-2Interleukin-2 Receptor alpha SubunitCytokines

Autor:innen und Institutionen

  • Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.

ORCID-Profile: Brian T Orcutt-Jahns, Peter C Emmel, Scott D Taylor, Aaron S Meyer

Förderung

  • NIAID NIH HHS

Zitieren

APA

Orcutt-Jahns, B. T., Emmel, P. C., Snyder, E. M., Taylor, S. D., & Meyer, A. S. (2023). Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells. Science Signaling. https://doi.org/10.1126/scisignal.adg0699

Vancouver

Orcutt-Jahns BT, Emmel PC, Snyder EM, Taylor SD, Meyer AS. Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells. Science Signaling. 2023. doi:10.1126/scisignal.adg0699

BibTeX
@article{OrcuttJahns2023,
  author = {Orcutt-Jahns, Brian T and Emmel, Peter C and Snyder, Eli M and Taylor, Scott D and Meyer, Aaron S},
  title = {Multivalent, asymmetric IL-2–Fc fusions show enhanced selectivity for regulatory T cells},
  journal = {Science Signaling},
  year = {2023},
  doi = {10.1126/scisignal.adg0699}
}
Kostenlos starten →